drugset / Trial / NCT01136278

Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA)

NCT01136278

Phase 1 Completed 16 enrolled University Hospital, Basel, Switzerland
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to determinate the effect of a pre-treatment with centrally acting alpha2-receptor agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). The investigators hypothesize that clonidine will attenuate the subjective and cardiovascular response to MDMA.

Timeline

Start
2010-07
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Clonidine Other / unclassified 150 ug Oral
Subject Midomafetamine Unknown 125 mg